Literature DB >> 26503736

Lysozyme in breast milk is a selection factor for bifidobacterial colonisation in the infant intestine.

J Minami1, T Odamaki1, N Hashikura1, F Abe1, J Z Xiao1.   

Abstract

The objective of this work was to study the residential characteristics of bifidobacteria, which can be classified as either human-residential bifidobacteria (HRB) or non-HRB. We investigated the growth of different strains of HRB and non-HRB in human breast milk with the aim of understanding the mechanisms involved in the unique habitation of each taxon. The growth of 37 strains of different bifidobacterial species or subspecies in breast milk was investigated by incubating each under anaerobic conditions at 37 °C. The tolerance of each strain to either egg white or human lysozyme was compared. Among the infant-type HRB strains, all strains of Bifidobacterium longum subsp. infantis and Bifidobacterium breve grew well in breast milk, but the growth characteristics of B. longum subsp. longum and B. bifidum were strain-dependent. In contrast, the tested strains of adult-type HRB and non-HRB generally failed to grow and died after incubation in breast milk. Most infant-type HRB strains were tolerant to high concentrations of lysozyme, while adult-type HRB strains possessed intermediate tolerance to lysozyme, and non-HRB strains were susceptible to lysozymes of egg white or human origin. These data suggest that breast milk lysozyme content plays a central role in the exclusion of non-HRB, while other factors, together with lysozyme content, are involved in the growth inhibition of adult-type strains in human milk. Our results suggest that infant-type HRB strains would be suitable candidates for use as infant probiotics.

Entities:  

Keywords:  Bifidobacterium; human breast milk; lysozyme; oligosaccharides

Mesh:

Substances:

Year:  2015        PMID: 26503736     DOI: 10.3920/BM2015.0041

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  6 in total

1.  Persistence of Anti SARS-CoV-2 Antibodies in Breast Milk from Infected and Vaccinated Women after In Vitro-Simulated Gastrointestinal Digestion.

Authors:  Joaquim Calvo-Lerma; Pierre Bueno-Llamoga; Christine Bäuerl; Erika Cortés-Macias; Marta Selma-Royo; Francisco Pérez-Cano; Carles Lerin; Cecilia Martínez-Costa; Maria Carmen Collado
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

Review 2.  Insights into the reason of Human-Residential Bifidobacteria (HRB) being the natural inhabitants of the human gut and their potential health-promoting benefits.

Authors:  Chyn Boon Wong; Toshitaka Odamaki; Jin-Zhong Xiao
Journal:  FEMS Microbiol Rev       Date:  2020-05-01       Impact factor: 16.408

3.  Neonatal oral fluid as a transmission route for bifidobacteria to the infant gut immediately after birth.

Authors:  Kazuya Toda; Ken Hisata; Takumi Satoh; Noriko Katsumata; Toshitaka Odamaki; Eri Mitsuyama; Takane Katayama; Tetsuya Kuhara; Kohzo Aisaka; Toshiaki Shimizu; Jin-Zhong Xiao
Journal:  Sci Rep       Date:  2019-06-18       Impact factor: 4.379

4.  Exclusively Breastfed Infant Microbiota Develops over Time and Is Associated with Human Milk Oligosaccharide Intakes.

Authors:  Ali Sadiq Cheema; Michelle Louise Trevenen; Berwin Ashoka Turlach; Annalee June Furst; Ana Sophia Roman; Lars Bode; Zoya Gridneva; Ching Tat Lai; Lisa Faye Stinson; Matthew Scott Payne; Donna Tracy Geddes
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

5.  Human milk immunomodulatory proteins are related to development of infant body composition during the first year of lactation.

Authors:  Zoya Gridneva; Ching T Lai; Alethea Rea; Wan J Tie; Leigh C Ward; Kevin Murray; Peter E Hartmann; Donna T Geddes
Journal:  Pediatr Res       Date:  2020-05-21       Impact factor: 3.756

Review 6.  Antimicrobial Proteins and Peptides in Early Life: Ontogeny and Translational Opportunities.

Authors:  Anna J Battersby; Jasmeet Khara; Victoria J Wright; Ofer Levy; Beate Kampmann
Journal:  Front Immunol       Date:  2016-08-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.